CD1d expression in glioblastoma is a promising target for NKT cell-based cancer immunotherapy

Glioblastoma is the most common and aggressive type of brain tumor with high recurrence and fatality rates. Although various therapeutic strategies have been explored, there is currently no effective treatment for glioblastoma. Recently, the number of immunotherapeutic strategies has been tested for...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cancer Immunol Immunother
Egile Nagusiak: Hara, Ayaka, Koyama-Nasu, Ryo, Takami, Mariko, Toyoda, Takahide, Aoki, Takahiro, Ihara, Fumie, Kobayashi, Masayoshi, Hirono, Seiichiro, Matsutani, Tomoo, Nakayama, Toshinori, Iwadate, Yasuo, Motohashi, Shinichiro
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Springer Berlin Heidelberg 2020
Gaiak:
Original Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC8053161/
https://ncbi.nlm.nih.gov/pubmed/33128583
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00262-020-02742-1
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak